Physician profile

Barry Waters

Coral Springs, FL

NPI 1144227927

$7,588.46

in general payments reported to CMS, 2019-2025

24 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $1,774.19 2019-2021
Abbvie INC. $834.03 2019-2022
Lilly USA, LLC $610.48 2019-2022
Pfizer INC. $562.25 2019-2021
E.R. Squibb & Sons, L.L.C. $526.00 2019-2021
Novartis Pharmaceuticals Corporation $451.53 2019-2021
Ucb, INC. $387.68 2019-2021
Janssen Biotech, INC. $350.25 2019-2021
Glaxosmithkline, LLC. $330.71 2019-2021
Horizon Therapeutics Plc $254.23 2019-2021
Mallinckrodt Enterprises LLC $242.19 2019
Celgene Corporation $183.75 2019
Genzyme Corporation $172.93 2019-2020
Radius Health, INC. $162.34 2019-2021
Genentech USA, INC. $145.04 2019-2020
Show all 24 companies
CompanyGeneral paymentsYearsTop products
Sobi, INC $137.19 2019-2020
Mallinckrodt Hospital Products INC. $134.71 2020
Sanofi-Aventis U.S. LLC $116.34 2019-2021
Actelion Pharmaceuticals US, INC. $58.88 2020-2021
Medexus Pharma, INC. $56.34 2019
Pacira Therapeutics, INC. $48.72 2019-2020
Astrazeneca Pharmaceuticals Lp $16.73 2021
Cumberland Pharmaceuticals, INC. $16.35 2021
Merck Sharp & Dohme LLC $15.60 2020

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Barry Waters

$7,588.46

in general payments reported 2019-2025

Years
2019-2022
Top company
Amgen INC.

https://glasscript.com/doctor/97316/barry-waters

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.